People
Biogen is bolstering its multiple sclerosis (MS) pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic, MR-004.
For Terry Coelho, being CFO is about becoming a trusted strategic partner across the business. It’s about building bridges.
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
Athira investor Richard Kayne appears to be making a strong push for Dr. Ronald Krall, former chief medical officer of GlaxoSmithKline, to run the company, despite protests from Athira’s board.
BioSpace sat down with Sven Kili, 2022 ISCT Annual Meeting co-chair, to preview the event, which will focus on 4 key subject areas including launch and commercialization of cell and gene therapies.
David Sabatini has withdrawn his name for consideration for a faculty post at New York University Langone Health.
Biogen announced the leadership change in its quarterly financial report. Michel Vounatsos plans to depart the company when a new CEO is found.
Humacyte’s engineered blood vessels, human acellular vessels, are in a position to take tissue regeneration from a laboratory possibility to a commercial reality.
What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules. The company has 14 small molecule drugs in development.
Emergent BioSolutions Founder and former chief executive officer Fuad El-Hibri has died, the company reported.
PRESS RELEASES